ATLANTA, Dec. 11, 2012 /PRNewswire/ -- CardioMEMS, Inc., an Atlanta-based medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, announced today that it has been honored as the 2012 recipient of the Intel Innovation Award. Founder and CEO Jay Yadav, M.D., was presented with the award on December 4th during the annual Health IT Leadership Summit held at the historic Fox Theatre in Atlanta, GA.
"CardioMEMS unites two areas where Georgia has strengths – health IT and medical devices," said David B. Hartnett, Vice President, Bioscience & Health IT Development, Metro Atlanta Chamber. "This truly innovative company integrates these two disciplines to create advanced technology that holds huge promise for heart failure patients. We are proud that they are part of the Atlanta healthcare community, and look forward to watching their continued success."
"It was a challenging decision, given the high level of competition for this award," said Dan Rivera, Area Director, Intel Americas. "Ultimately, CardioMEMS was chosen as the winner based on its ground-breaking technology and novel use of health IT to reduce the burden on our healthcare system."
"We are honored to be recognized by Intel, a leader in innovative solutions," said Dr. Yadav. "This is a testament to the extraordinary efforts of the CardioMEMS team to generate precise, timely, actionable information to address the tremendous burden heart failure places on the U.S. healthcare system and on patients suffering from this debilitating disease. We are fortunate to have the considerable support of the Technology Association of Georgia, the Metro Atlanta Chamber and the Georgia Department of Economic Development as we continue to bring CardioMEMS' revolutionary technology to market."
About CardioMEMS, Inc.
CardioMEMS is a medical device company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body. The Company's technology platform is designed to improve the management of severe chronic cardiovascular diseases such as aneurysms, heart failure and hypertension. CardioMEMs miniature wireless sensors can be implanted using minimally-invasive techniques and transmit cardiac output, blood pressure and heart rate data which are critical to the management of patients. The sensors are designed to be permanently implanted into the heart and blood vessels due to their small size, durability and lack of wires and batteries. Using radiofrequency energy, the sensors transmit real-time data to external electronic readers, which then communicate this information to the patient's physician. The Company developed this technology based on the belief that frequent, on-demand, real-time monitoring of vital information enables proactive patient management, which holds the promise of reducing hospitalizations, improving a patient's quality of life and delivering more efficient and cost effective health care. More information about the CardioMEMs is located at www.cardiomems.com.
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company's products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.
CardioMEMS, Champion and the CardioMEMS logo are registered trademarks of CardioMEMS, Inc.
Caution: The Champion Heart Failure Monitoring System is an investigational device limited by federal law to investigational use.
SOURCE CardioMEMS, Inc.